Fig. 6

IL-23 induces pain with a requirement for GM-CSF, TNF, CCL17, and cyclooxygenase activity. a WT mice received an intraplantar (i.pl.) injection of saline or IL-23 (50 ng, 100 ng, or 200 ng). Pain (incapacitance meter) was measured. b–d An i.pl. injection of saline or IL-23 (200 ng) was given to b WT and GM-CSF^−/− mice, c WT and Tnf^−/− mice, and d WT and Ccl17^E/E mice. Pain was measured. e WT mice received i.pl. IL-23 (200 ng) with or without indomethacin (12.5 μg/paw i.pl. at t = 0) on day 0. Pain was measured. Data are expressed as mean ± SEM; a WT female mice (saline, n = 5; 50 ng, n = 10; 100 ng, n = 10; 200 ng, n = 15), b–d WT, GM-CSF^−/−, Tnf^−/−, and Ccl17^E/E male mice (saline, n = 6; IL-23, n = 10), e WT female mice (saline, n = 10; indomethacin, n = 10). For statistical analysis, a two-way ANOVA was used. **P < 0.01, saline vs. IL-23 (100 ng). ^#P < 0.05, ^##P < 0.01, ^####P < 0.0001, saline vs. IL-23 (200 ng). ^P < 0.05, ^^P < 0.01, WT IL-23 vs. GM-CSF^−/− IL-23, Tnf^−/− IL-23, or Ccl17^E/E IL-23, respectively; IL-23 + saline vs. IL-23 + indomethacin